NEW YORK (GenomeWeb News) – Oxford Gene Technology announced on Tuesday the opening of an office in Tarrytown, NY, to support and grow its US business.
Specifically, the office will seek to expand OGT's CytoSure cytogenetics arrays and Genefficiency next-generation sequencing operations. OGT will provide support and training to its existing US customers at the new office, and added that sales and support positions have been created with additional positions to be created in the coming weeks.
According to the UK firm, the US is the world's largest cytogenetics market "and is critical to the development of OGT's clinical and genomic services business."
OGT provides clinical genetics and diagnostics solutions directed at molecular medicine. CytoSure and Genefficiency comprise its Clinical & Genomic Solutions business. Its other business, Diagnostic Biomarkers, uses next-generation sequencing to discover biomarkers for the early detection of cancers, such as colorectal, prostate, and pancreatic cancers, as well as systemic lupus erythematosus.